Angiotensin II receptor blockers and risk of cancer in patients with systemic hypertension

American Journal of Cardiology

Volumn 107, Issue 7, 2011, Pages 1028-1033

  Huang, Chin Chou ^a,b   Chan, Wan Leong ^a   Chen, Yu Chun ^a,c   Chen, Tzeng Ji ^a,b   Lin, Shing Jong ^a,b   Chen, Jaw Wen ^a,b   Leu, Hsin Bang ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; EPROSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; TASOSARTAN; TELMISARTAN; VALSARTAN;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; LONG-TERM CARE; MALE; MIDDLE AGED; NEOPLASMS; POPULATION SURVEILLANCE; RISK; TAIWAN;

EID: 79952773620     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.11.026     Document Type: Article

References (29)

1. M. Burnier Angiotensin II type 1 receptor blockers Circulation 103 2001 904 912 (Pubitemid 32163892)
2. M.A. Pfeffer, J.J. McMurray, E.J. Velazquez, J.L. Rouleau, L. Køber, A.P. Maggioni, S.D. Solomon, K. Swedberg, F. Van de Werf, H. White, J.D. Leimberger, M. Henis, S. Edwards, S. Zelenkofske, M.A. Sellers, R.M. Califf Valsartan in Acute Myocardial Infarction Trial Investigators Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both N Engl J Med 349 2003 1893 1906 (Pubitemid 37409706)
3. S. Yusuf, K.K. Teo, J. Pogue, L. Dyal, I. Copland, H. Schumacher, G. Dagenais, P. Sleight, C. Anderson ONTARGET Investigators Telmisartan, ramipril, or both in patients at high risk for vascular events N Engl J Med 358 2008 1547 1559 (Pubitemid 351522739)
4. C.B. Granger, J.J. McMurray, S. Yusuf, P. Held, E.L. Michelson, B. Olofsson, J. Ostergren, M.A. Pfeffer, K. Swedberg CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting- enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776 (Pubitemid 37093917)
5. S. Yusuf, K. Teo, C. Anderson, J. Pogue, L. Dyal, I. Copland, H. Schumacher, G. Dagenais, P. Sleight Telmisartan Randomised Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) Investigators Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial Lancet 372 2008 1174 1183
6. O.V. Volpert, W.F. Ward, M.W. Lingen, L. Chesler, D.B. Solt, M.D. Johnson, A. Molteni, P.J. Polverini, and N.P. Bouck Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats J Clin Invest 98 1996 671 679 (Pubitemid 26349171)
7. S.I. Hii, D.L. Nicol, D.C. Gotley, L.C. Thompson, M.K. Green, and J.R. Jonsson Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma Br J Cancer 77 1998 880 883 (Pubitemid 28101773)
8. A.F. Lever, D.J. Hole, C.R. Gillis, I.R. McCallum, G.T. McInnes, P.L. MacKinnon, P.A. Meredith, L.S. Murray, J.L. Reid, and J.W. Robertson Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 352 1998 179 184 (Pubitemid 28327802)
9. S. Friis, H.T. Sørensen, L. Mellemkjaer, J.K. McLaughlin, G.L. Nielsen, W.J. Blot, and J.H. Olsen Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark Cancer 92 2001 2462 2470 (Pubitemid 33029093)
10. J.B. Christian, K.L. Lapane, A.L. Hume, C.B. Eaton, M.A. Weinstock VATTC Trial Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial J Natl Cancer Inst 100 2008 1223 1232
11. I. Sipahi, S.M. Debanne, D.Y. Rowland, D.I. Simon, and J.C. Fang Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials Lancet Oncol 11 2010 627 636
12. Bureau of National Health Insurance 2001 National Health Insurance Annual Statistical Report 2002 Bureau of National Health Insurance Taipei, Taiwan
13. C.C. Huang, Y.C. Chen, H.B. Leu, T.J. Chen, S.J. Lin, W.L. Chan, and J.W. Chen Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention Am J Cardiol 105 2010 1705 1709
14. WHO Collaborating Center for Drug Statistics Methodology ATC Index with DDDs 2003 2003 World Health Organization Oslo, Norway
15. G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A.M. Heagerty, S.E. Kjeldsen, S. Laurent, K. Narkiewicz, L. Ruilope, A. Rynkiewicz, R.E. Schmieder, H.A. Struijker Boudier, A. Zanchetti, A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, G. Filippatos, C. Funck-Brentano, I. Hellemans, S.D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J.L. Zamorano, S.E. Kjeldsen, S. Erdine, K. Narkiewicz, W. Kiowski, E. Agabiti-Rosei, E. Ambrosioni, R. Cifkova, A. Dominiczak, R. Fagard, A.M. Heagerty, S. Laurent, L.H. Lindholm, G. Mancia, A. Manolis, P.M. Nilsson, J. Redon, R.E. Schmieder, H.A. Struijker-Boudier, M. Viigimaa, G. Filippatos, S. Adamopoulos, E. Agabiti-Rosei, E. Ambrosioni, V. Bertomeu, D. Clement, S. Erdine, C. Farsang, D. Gaita, W. Kiowski, G. Lip, J.M. Mallion, A.J. Manolis, P.M. Nilsson, E. O'Brien, P. Ponikowski, J. Redon, F. Ruschitzka, J. Tamargo, P. van Zwieten, M. Viigimaa, B. Waeber, B. Williams, J.L. Zamorano The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 28 2007 1462 1536
16. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
17. M.D. Flather, S. Yusuf, L. Køber, M. Pfeffer, A. Hall, G. Murray, C. Torp-Pedersen, S. Ball, J. Pogue, L. Moy, and E. Braunwald Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients Lancet 355 2000 1575 1581 (Pubitemid 30240501)
18. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
19. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy Lancet 355 2000 253 259
20. S.E. McDowell, J.J. Coleman, and R.E. Ferner Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine BMJ 332 2006 1177 1181
21. K.S. Woo, R.M. Norris, and G. Nicholls Racial difference in incidence of cough with angiotensin-converting enzyme inhibitors (a tale of two cities) Am J Cardiol 75 1995 967 968
22. S. Julius, S.E. Kjeldsen, M. Weber, H.R. Brunner, S. Ekman, L. Hansson, T. Hua, J. Laragh, G.T. McInnes, L. Mitchell, F. Plat, A. Schork, B. Smith, A. Zanchetti VALUE Trial Group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2004 2022 2031 (Pubitemid 38781102)
23. S. Wilop, S. von Hobe, M. Crysandt, A. Esser, R. Osieka, and E. Jost Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy J Cancer Res Clin Oncol 135 2009 1429 1435
24. F. Deshayes, and C. Nahmias Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 16 2005 293 299 (Pubitemid 41206635)
25. D.R. Soto-Pantoja, J. Menon, P.E. Gallagher, and E.A. Tallant Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor Mol Cancer Ther 8 2009 1676 1683
26. J. Folkman, K. Watson, D. Ingber, and D. Hanahan Induction of angiogenesis during the transition from hyperplasia to neoplasia Nature 339 1989 58 61 (Pubitemid 19115892)
27. E. Escobar, T.S. Rodrguez-Reyna, O. Arrieta, and J. Sotelo Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer Curr Vasc Pharmacol 2 2004 385 399 (Pubitemid 39200189)
28. L. Lindberg, D. Nielsen, B.V. Jensen, J. Eriksen, and T. Skovsgaard Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncologica 43 2004 142 152 (Pubitemid 38478900)
29. H. Abali, I.H. Gll, H. Engin, I.C. Haznedarolu, M. Erman, and G. Tekuzman Old antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists Med Hypotheses 59 2002 344 348